Prelude Therapeutics Quote - PRLD

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

2.09

Bid

1.99

Offer

2.11

Volume

451

0.00 Day's Range 0.00

1.66 52 Week Range 6.80

Market Cap

115.001M

Previous Close

2.01

Open

Last Trade

2.06

Last Trade Time

23:05:58

Financial Volume

VWAP

Average Volume (3m)

297,987

Shares Outstanding

55,024,470

Dividend Yield

PE Ratio

-0.91

Earnings Per Share (EPS)

-2.21

Revenue

Net Profit

-121.83M

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need. Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.preludetx.com

Headquarters

Wilmington, Delaware, USA

Founded

Prelude Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PRLD. The last closing price for Prelude Therapeutics was US$2.01. Over the last year, Prelude Therapeutics shares have traded in a share price range of US$ 1.66 to US$ 6.80.

Prelude Therapeutics currently has 55,024,470 shares in issue. The market capitalisation of Prelude Therapeutics is US$110.60 million. Prelude Therapeutics has a price to earnings ratio (PE ratio) of -0.91.

Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

- Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4-mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789...

Form 8-K - Current report

Prelude Therapeutics Announces Publication of Abstract for Presentation at the European Society of Medical Oncology (ESMO) Congress 2024

PRT3789, a novel, highly-selective SMARCA2 degrader in patients with advanced solid tumors with a SMARCA4 mutation oral session presentation: September 13, 2024, 4:00 PM CEST (10:00 AM EST...

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because of the complementary nature of the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.03	-1.41509433962	2.12	2.25	1.94	189675	2.09691476	CS
4	-3.14	-60.0382409178	5.23	5.53	1.94	479298	2.98708521	CS
12	-1.62	-43.6657681941	3.71	6.8	1.94	297987	4.09887344	CS
26	-2.43	-53.7610619469	4.52	6.8	1.94	163297	4.08218941	CS
52	-0.69	-24.8201438849	2.78	6.8	1.66	153081	3.65218877	CS
156	-29.47	-93.3776932826	31.56	32.77	1.66	178666	8.01385585	CS
260	-23.67	-91.8866459627	25.76	95.375	1.66	191241	19.03740668	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
ELABElevai Labs Inc	US$ 0.1517 (78.05%)	153.71M
PEGYPineapple Energy Inc	US$ 0.1645 (43.17%)	96.55M
RZLVRezolve AI Ltd	US$ 8.60 (26.10%)	878.33k
EVGOEVgo Inc	US$ 4.9201 (25.19%)	3M
WHLRWheeler Real Estate Investment Trust Inc	US$ 16.60 (23.97%)	1.25M
KXINKaixin Holdings	US$ 0.2598 (-24.06%)	9.18M
HOLOMicroCloud Hologram Inc	US$ 0.27 (-21.51%)	6.67M
DUOFangDD Network Group Ltd	US$ 3.5103 (-19.86%)	2.26M
MTCMMTec Inc	US$ 0.615 (-19.81%)	2.17M
ANIPANI Pharmaceuticals Inc	US$ 46.12 (-19.79%)	25
ELABElevai Labs Inc	US$ 0.1517 (78.05%)	153.71M
PEGYPineapple Energy Inc	US$ 0.1645 (43.17%)	96.55M
MLGOMicroAlgo Inc	US$ 0.3459 (11.58%)	39.06M
CDTConduit Pharmaceuticals Inc	US$ 0.1081 (13.79%)	26.7M
XPONExpion360 Inc	US$ 0.045 (-3.43%)	9.71M